Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion type Assertion NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_head.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion wasGeneratedBy ECO_0000203 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion wasDerivedFrom befree-2016 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion SIO_000772 12615701 NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion evidence source_evidence_literature NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.
- NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_assertion description "[Clinical studies testing the efficacy of COX inhibition as adjuvant therapy for ovarian cancer may see more beneficial effects with adjuvant therapy with either a COX-1 selective or nonselective cyclooxygenase inhibitor as compared with a COX-2 selective drug.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385525.RAZG1lPBF8o2mz1VV9mXgaHnfFdMT-l_0LcXqJfq1x3Wg130_provenance.